Study population
infections, gout, organ dysfunction, acute illness, RA, trauma
SYSTEMIC VASCULITIS, URINARY TRACT INFECTIONS, GENITAL HERPES, SYSTEMIC LUPUS ERYTHEMATOSUS, INFECTIONS, SPONDYLOARTHROPATHY, OSTEOMYELITIS, HERPES ZOSTER, GOUT, RECURRENT SINUSITIS
Eligible patients were males or females diagnosed with RA (according to the 2010 American College of Rheumatology [ACR]/EULAR criteria for at least 6 months and on anti-RA treatments for 12 weeks, without significant concomitant illness, recent severe infections or organ dysfunction) (Key exclusion criteria were history of and/or current clinically significant illness that had not been stable for 3 months prior to enrollment, or an acute illness, planned medical/surgical procedure, or trauma within 2 months prior to enrollment, use of traditional Chinese medicines, over-the-counter emergency anti-inflammatory drugs, or any active/attenuated vaccine within 4 weeks prior to screening, current or previous use of IL-6 antagonists, or other biological modifying anti-rheumatics within 12 weeks or more (as required) prior screening, presence of other systemic inflammatory conditions (eg, systemic lupus erythematosus, spondyloarthropathy, systemic vasculitis, gout, and systemic vasculitis), any acute, chronic, or recurrent infections (eg, recurrent sinusitis, genital herpes, herpes zoster, osteomyelitis, and urinary tract infections) during the screening period, subjects who were positive for human immunodeficiency virus, hepatitis C virus antibody, or hepatitis B surface antigen and those participating in other clinical trials.